- Home
- ALL vs ZTS Comparison
ALL vs ZTS Comparison
Compare ALL & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALL | ZTS |
|---|---|---|
| Founded | 1931 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.0B | 53.9B |
| IPO Year | 1993 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ALL | ZTS |
|---|---|---|
| Price | $192.03 | $125.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | ★ $225.07 | $174.60 |
| AVG Volume (30 Days) | 1.8M | ★ 4.8M |
| Earning Date | 02-04-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.08% | 1.70% |
| EPS Growth | ★ 99.54 | 11.64 |
| EPS | ★ 30.82 | 5.94 |
| Revenue | ★ $66,846,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | N/A | $3.04 |
| Revenue Next Year | $6.05 | $4.96 |
| P/E Ratio | ★ $6.24 | $21.00 |
| Revenue Growth | ★ 7.07 | 2.68 |
| 52 Week Low | $176.00 | $115.25 |
| 52 Week High | $215.89 | $177.40 |
Technical Indicators
Market Signals| Indicator | ALL | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 49.11 |
| Support Level | $194.56 | $123.32 |
| Resistance Level | $215.00 | $126.50 |
| Average True Range (ATR) | 4.65 | 2.69 |
| MACD | -1.83 | -0.10 |
| Stochastic Oscillator | 0.00 | 21.94 |
Price Performance
Historical ComparisonAbout ALL Allstate Corporation (The)
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.